Review the clinical considerations, therapeutic history, and need for symptom improvement that led to nonstimulant ADHD treatment for 9-year-old Sarah.
Review the clinical considerations, therapeutic history, and need for symptom improvement that led to nonstimulant ADHD treatment for 9-year-old Sarah.
Review the clinical considerations, therapeutic history, and need for symptom improvement that led to nonstimulant ADHD treatment for 17-year-old Felicity.
Review the clinical considerations, therapeutic history, and need for symptom improvement that led to nonstimulant ADHD treatment for 17-year-old Felicity.
Do your adult patients (18 years and older) need a nonstimulant option to treat their Attention-Deficit/Hyperactivity Disorder (ADHD)? Read more about a nonstimulant ADHD medication approved for adults.
Do your adult patients (18 years and older) need a nonstimulant option to treat their Attention-Deficit/Hyperactivity Disorder (ADHD)? Read more about a nonstimulant ADHD medication approved for adults.
Learn about some important factors for physicians and patients to consider before initiating an ADHD treatment plan. Read about monitoring, screening, drug interactions, and more before treating your patients.
Learn about some important factors for physicians and patients to consider before initiating an ADHD treatment plan. Read about monitoring, screening, drug interactions, and more before treating your patients.
Provide your patients with key information about their ADHD medication. Educate them on how they should take the medication, the possible side effects, and when to reach out for help.
Provide your patients with key information about their ADHD medication. Educate them on how they should take the medication, the possible side effects, and when to reach out for help.
Listen to David, an adult with ADHD, share his personal ADHD journey with various treatment experiences, including his current treatment with a nonstimulant medication.
Listen to David, an adult with ADHD, share his personal ADHD journey with various treatment experiences, including his current treatment with a nonstimulant medication.
In this podcast, listen as Dr. Corey Hebert and Dr. Napoleon Higgins discuss strategies to optimize care transitions for patients with ADHD from pediatric services (ages 6 to 17 years) to adult services (18 years and older).
In this podcast, listen as Dr. Corey Hebert and Dr. Napoleon Higgins discuss strategies to optimize care transitions for patients with ADHD from pediatric services (ages 6 to 17 years) to adult services (18 years and older).
In this podcast, Dr. Chlldress discusses her experience with treating Attention-Deficit/Hyperactivity Disorder (ADHD) patients and compares her findings in practice with those in her clinical studies.
In this podcast, Dr. Chlldress discusses her experience with treating Attention-Deficit/Hyperactivity Disorder (ADHD) patients and compares her findings in practice with those in her clinical studies.
In this podcast, Dr. Chlldress...
03/01/2023
Psych Congress Network
About Supernus
We are a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Over the last 30 years, we have built an extensive expertise in product development. Initially, we were a stand-alone development organization, then a U.S. subsidiary of Shire plc and, in late 2005, we became Supernus Pharmaceuticals, Inc.
Our Mission: To improve the lives of patients suffering from diseases of the central nervous system (CNS). We market our products within the United States through our own specialty sales forces. We also seek strategic collaborations with other pharmaceutical companies to license our products outside the United States.